BMS-986020
BMS-986020 (BMS986020, AM-152) is a potent, selective, orally available LPA1 receptor antagonist for treating idiopathic pulmonary fibrosis.Cystic Fibrosis, Phase 2 Clinical (In Vitro) :BMS-986020 (0.1-10 nM; pre-incubated) concentration-dependent displacement of [18F]BMT-083133 binding is observed in LPA1+ cells and lung sections. At 0.1 nM, the percent displacement in healthy mice, bleomycin mice, and IPF lungs is 18%, 24%, and 31%, respectively. At 10 nM, the percent displacement is 73%, 76%, and 64%, respectively.BMT-083133, a radioligand targeting LPA1 is developed as a translational research tool for assessment of lung LPA1 engagement of BMS-986020 using in vitro autoradiography (ARG) .
Product Specifications
CAS Number
1257213-50-5
Product Name Alternative
BMS 986020 | BMS986020 | AM-152 | AM152 | AM 152
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 64 mg/mL
Smiles
CC1=NOC (=C1NC (=O) OC (C) C2=CC=CC=C2) C3=CC=C (C=C3) C4=CC=C (C=C4) C5 (CC5) C (=O) O
Molecular Formula
C29H26N2O5
Molecular Weight
482.5271
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[ (1R) -1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]-
Available Sizes
Explore Other Products
Browse additional items from our catalog
